Fabien Xuereb
Overview
Explore the profile of Fabien Xuereb including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
212
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Meireles V, Airaud C, Demay E, Cazanave C, Xuereb F, Lazaro P, et al.
Eur J Clin Microbiol Infect Dis
. 2025 Feb;
PMID: 39992533
Purpose: Obese patients treated with daptomycin at 4 mg/kg have a 30% increased drug exposure, potentially raising the risk of adverse events (AEs) like rhabdomyolysis. Given limited data on the...
2.
Lahouati M, Oudart M, Alzieu P, Chapouly C, Petitcollin A, Xuereb F
Clin Transl Sci
. 2025 Jan;
18(1):e70100.
PMID: 39834151
Penetration of antimicrobial treatments into the cerebrospinal fluid is essential to successfully treat infections of the central nervous system. This penetration is hindered by different barriers, including the blood-brain barrier,...
3.
Lahouati M, Tinevez C, Gabriel F, Xuereb F, Lefranc M, Dauchy F
J Bone Jt Infect
. 2024 Nov;
9(5):213-215.
PMID: 39539735
Rezafungin, which only requires weekly administration, is a potential candidate for difficult-to-treat infections that require long-term antimicrobial treatment, such as bone and joint infections. We report the first case of...
4.
Lahouati M, Brousse X, Meireles V, Rignol L, Bientz L, Xuereb F, et al.
JAC Antimicrob Resist
. 2024 Nov;
6(6):dlae171.
PMID: 39512359
Objectives: The aim of this study is to describe the real-life use of temocillin in bone and joint infections (BJI). Patients And Methods: We performed a monocentric retrospective study, including...
5.
Huynh C, Crubezy I, Trin K, Perino J, Ong N, Ramaroson H, et al.
Ann Pharm Fr
. 2024 Jul;
82(6):1118-1133.
PMID: 39084283
Objectives: An increased risk of mortality and postoperative side effects led to aprotinin (Trasylol®) withdrawal from the market in 2008, but since 2018 aprotinin has again been used in France....
6.
Marque P, Leitao J, Dauchy F, Gerbouin O, Fabre T, Xuereb F, et al.
Infect Dis Now
. 2024 Apr;
54(4):104906.
PMID: 38580052
Objectives: Patients with bone and joint infections (BJI) are involved in a complex care pathway and require prolonged antimicrobial treatment. Some studies have suggested that a pharmacist-led telehealth intervention (TI)...
7.
Chambord J, Chauveau B, Djabarouti S, Vignaud J, Taton B, Moreau K, et al.
Transpl Int
. 2023 Dec;
36:11962.
PMID: 38089004
Our objective was to calculate an immunosuppressant possession ratio (IPR) to diagnose non-adherence at the time of antibody-mediated rejection (ABMR). IPR was defined as the ratio of number of pills...
8.
Cebe A, Dessane B, Gohier P, Bernadou J, Venet A, Xuereb F, et al.
Pharmaceutics
. 2023 Mar;
15(3).
PMID: 36986768
In the context of essential drug shortages, this article reports a proof of concept for the hospital preparation of a 2% propofol injectable nanoemulsion. Two processes for propofol were assessed:...
9.
Perino J, Gouverneur A, Bonnet F, Lahouati M, Bernard N, Breilh D, et al.
Therapie
. 2021 Jul;
76(6):629-637.
PMID: 34243901
Purpose: To date, how medication reconciliation (MR) could be prioritized in younger patients remains poorly evaluated. This study aimed at assessing whether a MR prioritization strategy based on the identification...
10.
Chambord J, Couzi L, Merville P, Moreau K, Xuereb F, Djabarouti S
Ther Adv Chronic Dis
. 2021 Apr;
12:20406223211005275.
PMID: 33868624
Aims: To assess the effect of a pharmacist-led intervention, using Barrows cards method, during the first year after renal transplantation, on patient knowledge about their treatment, medication adherence and exposure...